Search
DaxibotulinumtoxinA
go.drugbank.com/drugs/DB17929ApprovedInvestigationalIt is a botulinum toxin without accessory proteins purified from the bacterium _Clostridium botulinum_ type A,[L47840] the gram-positive anaerobic bacterium primarily present in soil. … [L47870] DAXI or DAXXIFY, a product of daxibotulinumtoxinA, incorporates RTP004, a proprietary synthetic stabilizing peptide for enhanced product stability.[A261080, A261085]
Categories: Botulinum Toxins, Type AViomycin
go.drugbank.com/drugs/DB06827ApprovedViomycin is a tuberactinomycin antibiotic that was used to treat Mycobacterium tuberculosis until it was replaced by the less toxic capreomycin. … These drugs bind RNA in bacterial ribosomes and inhibit protein synthesis. Viomycin was derived from the actinomycete _Streptomyces puniceus_.
Synonyms: Vinacetin AUstekinumab
go.drugbank.com/drugs/DB05679ApprovedInvestigationalUstekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. … L52830] and Wezlana [L52073] in Canada, and Uzpruvo in the EU.
Products: Stelara Solution for Injection in Pre-Filled Syringe 90 mg/1 mL, STELARA 90MG/1ML SOLUTION FOR INJECTION IN PREFILLED SYRINGELurbinectedin
go.drugbank.com/drugs/DB12674ApprovedInvestigationalLurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma,[A214325] chronic lymphocytic leukemia (CLL),[A214328] breast cancer, … [A214310] It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent found in extracts of the tunicate _Ecteinascidia turbinata_, with the primary difference being
Erythropoietin
go.drugbank.com/drugs/DB00016ApprovedInvestigationalErythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. … Epoetin alfa is a 165-amino acid erythropoiesis-stimulating glycoprotein produced in cell culture using recombinant DNA technology and is used for the treatment of patients with anemia associated with
Products: EPO STADA 2000IU/0.6ml Solution for Injection in a Pre-filled Syringe, EPO STADA 4000IU/0.4ml Solution for Injection in a Pre-filled SyringeAxicabtagene ciloleucel
go.drugbank.com/drugs/DB13915ApprovedInvestigationalThe drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. … [L40054] The development of resulted from early preclinical studies conducted by a group of researchers at the National Cancer Institute (NCI), who demonstrated that T cells expressing an anti-CD19 CAR
Synonyms: Autologous T cells transduced with retroviral vector encoding an anti-CD-19 CD28/CD3-zeta chimeric antigen receptorDesflurane
go.drugbank.com/drugs/DB01189ApprovedInvestigationalIt was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888] Desflurane was granted FDA approval on 18 September 1992.[L30285] … Desflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as [methoxyflurane], [sevoflurane], [enflurane], or [isoflurane].
Tyloxapol
go.drugbank.com/drugs/DB06439ApprovedInvestigationalTyloxapol is a non-ionic detergent often used as a surfactant.
Categories: Compounds used in a research, industrial, or household settingNecitumumab
go.drugbank.com/drugs/DB09559ApprovedInvestigationalWithdrawnNecitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). … It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression
Pemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigational[A193719] FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide variety of cancers including those of the urinary bladder, breast … [A193716] In April 2020, pemigatinib was approved by the FDA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously treated adult patients with a fibroblast